{"altmetric_id":4815711,"counts":{"readers":{"mendeley":14,"citeulike":0,"connotea":0},"total":{"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["neil_bodie"],"posts_count":1}},"selected_quotes":["Immune recognition of OxLDL in atherosclerosis highly conserved natural antibodies with the so-called T15 idiotype"],"citation":{"altmetric_jid":"4f6fa4f03cf058f610002cff","authors":["John F. Kearney"],"doi":"10.1172\/jci10426","endpage":"1685","first_seen_on":"2015-11-27T21:26:18+00:00","issns":["0021-9738"],"issue":"12","journal":"Journal of Clinical Investigation","last_mentioned_on":1448659558,"links":["http:\/\/www.jci.org\/articles\/view\/10426\/version\/1\/pdf\/render"],"pubdate":"2000-06-15T00:00:00+00:00","publisher_subjects":[{"name":"Medical And Health Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"1683","subjects":["medicine"],"title":"Immune recognition of OxLDL in atherosclerosis","type":"article","volume":"105","mendeley_url":"http:\/\/www.mendeley.com\/research\/immune-recognition-oxldl-atherosclerosis"},"altmetric_score":{"score":0.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":{"all":{"total_number_of_other_articles":6613942,"mean":6.1334676036573,"rank":5643467,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":6613942,"percentile":1},"similar_age_3m":{"total_number_of_other_articles":251104,"mean":9.2247023094109,"rank":198819,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":251104,"percentile":1},"this_journal":{"total_number_of_other_articles":5245,"mean":12.868981311976,"rank":4986,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":5245,"percentile":1},"similar_age_this_journal_3m":{"total_number_of_other_articles":99,"mean":17.30793877551,"rank":94,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":99,"percentile":1}}},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}},"mendeley":{"by_status":{"Professor > Associate Professor":3,"Researcher":4,"Student  > Ph. D. Student":2,"Student  > Master":2,"Other":1,"Student  > Bachelor":1,"Professor":1},"by_discipline":{"Medicine and Dentistry":4,"Agricultural and Biological Sciences":8,"Biochemistry, Genetics and Molecular Biology":2}}},"geo":{"twitter":{"US":1},"mendeley":{"AU":1,"DE":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/neil_bodie\/statuses\/670352891048144896","license":"gnip","citation_ids":[4815711],"posted_on":"2015-11-27T21:25:58+00:00","author":{"name":"Dr Neil Bodie","image":"https:\/\/pbs.twimg.com\/profile_images\/794481195023155200\/mS5CWXyF_normal.jpg","description":"DVM CEO http:\/\/paradigmimmunotherapeutics.com Developing disruptive technology for infectious agents & autoimmune diseases \u2764\ufe0f\ufe0fSoaring\u2708Follow\/Unfollow back","id_on_source":"neil_bodie","tweeter_id":"2910149688","geo":{"lt":34.14778,"ln":-118.14452,"country":"US"},"followers":12308},"tweet_id":"670352891048144896"}]}}